XYA02 / XYone Therap - LARVOL DELTA

Novel MUC1-C-ADC exhibits remarkable anti-tumor potency in the treatment of triple-negative breast cancer (TNBC) (ESMO 2025) - "Based on these, the final ADC candidate, XYA02, was selected...Phase I clinical trials are scheduled to initiate in mid-2026. Legal entity responsible for the study Xyone Therapeutics Inc."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • MUC1